Soleno Therapeutics Inc’s recently made public that its Shareholder Abingworth Bioventures VII LP acquired Company’s shares for reported $110.7 million on Aug 11 ’25. In the deal valued at $82.15 per share,1,347,522 shares were bought.
Then, Hirano Patricia C sold 3,830 shares, generating $316,971 in total proceeds. Upon selling the shares at $82.76, the insider now owns 13,206 shares.
Before that, PATRICIA HIRANO bought 3,830 shares. Soleno Therapeutics Inc shares valued at $316,971 were divested by the Officer at a price of $82.76 per share.
Wells Fargo initiated its Soleno Therapeutics Inc [SLNO] rating to an Overweight in a research note published on August 20, 2025; the price target was $123. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Stifel maintained its rating on December 02, 2024. It rated SLNO as “a Buy”.
Price Performance Review of SLNO
On Friday, Soleno Therapeutics Inc [NASDAQ:SLNO] saw its stock fall -1.76% to $68.57. Over the last five days, the stock has lost -4.27%. Soleno Therapeutics Inc shares have risen nearly 34.45% since the year began. Nevertheless, the stocks have risen 52.55% over the past one year. While a 52-week high of $90.32 was reached on 07/09/25, a 52-week low of $41.50 was recorded on 01/15/25.
Levels Of Support And Resistance For SLNO Stock
The 24-hour chart illustrates a support level at 67.63, which if violated will result in even more drops to 66.69. On the upside, there is a resistance level at 69.90. A further resistance level may holdings at 71.23.
How much short interest is there in Soleno Therapeutics Inc?
A steep rise in short interest was recorded in Soleno Therapeutics Inc stocks on 2025-07-31, growing by 0.69 million shares to a total of 6.04 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 5.35 million shares. There was a rise of 11.37%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 02, 2024 when Robert W. Baird resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $72.
